How'd you fix Precision Medicine Group's revenue issues in 2026?

Direct Answer

Precision Medicine Group is stuck in a commodity CRO trap—competing on price against IQVIA, ICON, and Parexel while watching oncology budgets tighten post-Blackstone/H&F ownership. The 2026 fix: anchor revenue to real-world-evidence outcomes, not FTE counts. Replace T&M staffing with outcome-linked contracts that tie payment to data quality, patient stratification accuracy, and regulatory wins. Build a "RWE-first" go-to-market layer using Komodo Health's oncology cohorts + Datavant's de-identification + your clinical ops. Stop selling "we do trials" and start selling "we know which oncology patients actually respond."

What's Actually Broken

The Biotech Funding Squeeze (2024–2026) Oncology sponsors have 40% fewer Phase 2/3 starts. CRO utilization is down. Margins compress because clients demand bundled RWE + traditional trial ops, but IQVIA and Syneos already own those stacks.

Your Commodity Problem You're competing on:

• Site network size (ICON has 100k+ sites)
• Cost per patient (Parexel, Labcorp Drug Development, PPD undercut)
• Speed (Syneos claims it faster)

You can't win there. PRECISIONAQ's post-acquisition integration hasn't created defensible separation.

RWE is the Wedge Oncology sponsors want RWE for:

• Patient baseline stratification ("which real-world cohorts match our trial eligibility?")
• Comparative effectiveness ("how does our drug perform vs. standard of care *today*?")
• Payer negotiation ("here's real-world progression-free survival")

IQVIA and Parexel sell RWE as a line item. You should sell it as the *core contract vehicle*.

The 2026 Fix Playbook

Move 1: Build the Oncology RWE Engine (Q1–Q2)

• Partner with Komodo Health: Real-time oncology patient data (4M+ US records, treatment sequencing, biomarkers). Embed their API into your trial-matching module.
• Integrate Datavant: De-identified EHR + claims data linkage. This turns your "patient recruitment" into "sponsored cohort insights."
• Add Aetion: Causal inference for observational RWE (FDA-approved for regulatory submissions). Charge 2.5x your current trial ops rate for Aetion-powered outcome reports.
• H1 Insights optional: If budget allows, add H1's health equity layers (diverse patient populations + biomarker penetration).
• Outcome: One integrated proposal: "Patient Stratification + Trial Design + RWE Comparator Arm."

Move 2: Repackage Contracts (Q2)

• Kill pure FTE/T&M models. Transition 30% of current CRA revenue to "Outcome Contracts." Examples:
• "$X per enrolled patient if baseline mutation matches our prediction model" (Komodo data + your AI)
• "$Y per trial if RWE dropout rate within 2% of projection" (accountability)
• "$Z for regulatory dossier if RWE evidence meets FDA ICH standards" (de-risked)
• Keep traditional ops for defensive revenue, but frame it as "trial infrastructure for our RWE platform."

Move 3: New GTM Layer (Q2–Q3) Hire or partner with:

• Pavilion: Sales coaching for reps selling "RWE outcomes" (not trial sites). They'll transform your pitch from "we have 400 sites" to "we predict which 15% of your patients will respond."
• Bridge Group (or Klue): Competitive intel on IQVIA, Syneos, Parexel RWE pricing. Market your Komodo + Datavant stack as 60% faster patient ID than IQVIA's legacy data integration.
• Force Management: Sales methodology for multi-threaded selling (CFO + Chief Medical Officer + Regulatory). RWE decisions sit at the CFO level now.

Move 4: Anchor with One Table (Oncology CRO Revenue Model Shift)

Move 5: Week 1 CHRO Conversation In the first all-hands with your new Chief Medical/Commercial Officer:

• "We're not a CRO anymore; we're an Oncology RWE Company that *also* runs trials."
• Hire 8–12 data scientists (Komodo + RWE-trained). Retrain 20% of CRAs into "RWE customer success."
• Launch a pricing deck that leads with Komodo cohort sizes, not site counts.
• Set 2026 win metric: "Contracts where RWE is >40% of statement of work."

Bottom Line

Precision Medicine Group loses revenue growth because it competes like a 1990s CRO: on site density and cost. The 2026 turnaround is a pivot to RWE as the primary contract vehicle—using Komodo Health's oncology patient data, Datavant's de-ID, and Aetion's regulatory-grade analytics. This reframes you from "we run trials" to "we know which real-world patients match your drug, predict efficacy, and de-risk your regulatory path." Pavilion sells it, Bridge Group arms you against IQVIA, Force Management gets CFOs to sponsor it. Target: $18M new RWE revenue, 20% total growth, defensible margin. Requires Q1 partnerships + Q2 sales retraining, but pulls you out of commodity CRO hell.